论文部分内容阅读
抗体类药物近20年来蓬勃发展,目前全球上市的抗体药物已经有40多个品种,其治疗领域也从传统的癌症、自身免疫性疾病逐步扩展到抗感染和代谢性疾病等。2013年全球10大畅销药物中有6个是抗体类药物,包括3个自身免疫病治疗性药物和3个抗肿瘤抗体。单克隆抗体发展的同时也开启了对新结构、新功能抗体药物的探索,以期进一步优化抗体药物功能活性。抗体糖基化改造(afucosylation)、抗体-药物偶联(antibody drug conjugate,ADC)、双功能抗体(bispecific antibodies,BsAb)等都是当前抗体药物研发的热点领域。单克隆抗体能够特异性结合
Antibodies have thrived in the past 20 years. Currently, there are more than 40 kinds of antibody drugs marketed worldwide, and their therapeutic fields are gradually expanding from traditional cancer and autoimmune diseases to anti-infection and metabolic diseases. Six of the top 10 best-selling drugs in the world in 2013 were antibody-based, including three autoimmune diseases and three anti-tumor antibodies. The development of monoclonal antibodies also opened up the exploration of new structures and new functional antibody drugs in order to further optimize the functional activity of antibody drugs. Antibody afucosylation, antibody drug conjugate (ADC), bispecific antibodies (BsAb) and so on are the hotspot of the current antibody drug development. Monoclonal antibodies can specifically bind